RPRX Royalty Pharma plc

NASDAQ
$58.21

Royalty Pharma plc (RPRX) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is $1.18 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.2% since its last earnings release on August 5, 2026.

Royalty Pharma plc Beat Consensus Estimates, Raises Guidance, but Remains In-line with Estimates
Wednesday, August 5, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 7:00 AM ET
Earnings Whisper
-
vs $1.18
Rev est $872.69M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $59.80

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Royalty Pharma plc

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.

Sector

Financials

Industry

Diversified Investments

Held By 12 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.